Cargando…

Moxetumomab Pasudotox: First Global Approval

Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxet...

Descripción completa

Detalles Bibliográficos
Autor principal: Dhillon, Sohita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323103/
https://www.ncbi.nlm.nih.gov/pubmed/30357593
http://dx.doi.org/10.1007/s40265-018-1000-9